Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone?
View PDF Version
Redirect to Publisher's version
(Publisher's version.url.txt, 39 bytes)
Patients who have had a transient ischaemic attack or nondisabling ischaemic stroke of presumed arterial origin have an annual risk of death from all vascular causes, non-fatal stroke, or non-fatal myocardial infarction that ranges between 4% and 11% without treatment. In the secondary prevention of these vascular complications the use of aspirin has been the standard treatment for the past two decades. Discussions about the dose of aspirin have dominated the issue for some time, although there is no convincing evidence for any difference in effectiveness in the dose range of 30-1300 mg/day. A far greater problem is the limited degree of protection offered by aspirin: the accumulative evidence from trials with aspirin alone and only for cerebrovascular disease of presumed arterial origin as qualifying event indicates that a dose of aspirin of at least 30 mg/day prevents only 13% of serious vascular complications.
- Aspirin/*therapeutic use
- Brain Ischemia/*prevention & control
- Cerebral Arteries/*drug effects
- esps -2
- outcome event